| TTM
|
12/31/2025
|
12/31/2024
|
12/31/2023
|
12/31/2022
|
|
|---|---|---|---|---|---|
| Total Revenue
|
98,054 | 98,296 | 101,681 | 111,465 | 125,487 |
| Cost of Revenue
|
-43,559 | -39,294 | -39,418 | -43,100 | -47,182 |
|
Gross Profit
|
54,495 | 59,002 | 62,263 | 68,365 | 78,305 |
| Selling, General and Administrative Expenses
|
-37,264 | -37,030 | -36,624 | -38,698 | -42,556 |
|
Research and Development Expenses
|
-5,314 | -5,041 | -4,068 | -3,868 | -4,733 |
|
Operating Income/Expenses
|
-42,578 | -42,071 | -40,692 | -42,566 | -47,289 |
|
Total Operating Profit/Loss
|
11,917 | 16,931 | 21,571 | 25,799 | 31,016 |
| Total Net Finance Income/Expense
|
1,765 | 1,989 | 2,278 | 1,700 | 174 |
|
Other Income/Expense, Non-Operating
|
0 | 331 | -227 | 46 | -211 |
|
Non-Operating Income/Expenses, Total
|
1,765 | 2,320 | 2,051 | 1,746 | -37 |
|
Pretax Income
|
13,682 | 19,251 | 23,622 | 27,545 | 30,979 |
|
Provision for Income Tax
|
-3,442 | -4,667 | -5,707 | -6,825 | -7,327 |
|
Net Income from Continuing Operations
|
10,240 | 14,584 | 17,915 | 20,720 | 23,652 |
|
Net Income after Extraordinary Items and Discontinued Operations
|
10,240 | 14,584 | 17,915 | 20,720 | 23,652 |
|
Non-Controlling/Minority Interests
|
286 | 243 | 99 | 43 | -30 |
|
Net Income after Non-Controlling/Minority Interests
|
10,526 | 14,827 | 18,014 | 20,763 | 23,622 |
|
Net Income Available to Common Stockholders
|
10,526 | 14,827 | 18,014 | 20,763 | 23,622 |
|
Diluted Net Income Available to Common Stockholders
|
10,526 | 14,827 | 18,014 | 20,763 | 23,622 |
|
Common Dividend per Share
|
1.36 | 1.36 | 1.35 | 1.31 | 1.26 |
| Basic EPS
|
1.04 | 1.47 | 1.78 | 2.06 | 2.34 |
| Diluted EPS
|
1.04 | 1.47 | 1.78 | 2.06 | 2.34 |
|
Basic Weighted Average Shares Outstanding
|
10,094 | 10,094 | 10,094 | 10,094 | 10,094 |
|
Diluted Weighted Average Shares Outstanding
|
10,094 | 10,094 | 10,094 | 10,094 | 10,094 |
| Income Statement, Supplemental
|
|||||
|
EBIT
|
11,917 | 17,262 | 21,344 | 25,845 | 30,805 |
|
EBITDA
|
13,311 | 18,625 | 22,599 | 26,944 | 31,901 |
|
Normalized EBITDA
|
13,535 | 18,794 | 22,653 | 27,236 | 32,057 |
|
Normalized Income
|
10,407.65 | 14,712.10 | 17,955.93 | 20,939.65 | 23,771.10 |
|
Total Unusual Items
|
224 | 169 | 54 | 292 | 156 |
|
Total Unusual Items Excluding Goodwill
|
224 | 169 | 54 | 292 | 156 |
12/31/2022 - 8/1/2005
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade